Metagenomi Therapeutics, Inc. cash flow statement

In fiscal 2025, Metagenomi Therapeutics, Inc.'s operations generated −$88.9m of cash; it spent $574,000 on capital projects, leaving free cash flow of −$89.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Metagenomi Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMMar 2026
Cash from operations	−91	−109	−89	−87
Depreciation and amortisation	4	5	5	5
Stock-based pay	7	16	12	11
Capital spending	10	3	1	0
Free cash flow	−101	−112	−89	−88
Free cash flow after stock pay	−108	−128	−101	−99

US$ millions unless shown otherwise. Fiscal quarters.

Metagenomi Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026
Cash from operations	−26	−27	−26	−23	−21	−21	−24	−21
Depreciation and amortisation	1	1	1	1	1	1	1	1
Stock-based pay	5	3	3	3	3	3	3	3
Capital spending	1	1	0	0	0	0	0	0
Free cash flow	−27	−28	−27	−23	−21	−21	−24	−21
Free cash flow after stock pay	−31	−31	−30	−26	−25	−24	−26	−24

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: JANX vs MGX CRSP vs MGX ABEO vs MGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Metagenomi Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Metagenomi Therapeutics, Inc.